Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FKJG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,795
Award facts
- Contract value 100% obligated
- $5,795.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $5,795.49 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The award, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries firm fixed-price terms and no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy through which the Defense Logistics Agency establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products, including branded and generic prescription medications, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's established performance on numerous delivery orders across diverse therapeutic categories, including oncology treatments, immunosuppressants, emergency medications, and specialty pharmaceuticals, demonstrates its capability to fulfill the specialized medical supply requirements of the federal military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FKJG8?
SPE2DR26FKJG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FKJG8 worth?
The government has obligated $5,795 on SPE2DR26FKJG8.
Is contract SPE2DR26FKJG8 an order under another contract?
Yes. SPE2DR26FKJG8 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJG8 competed?
The extent of competition for SPE2DR26FKJG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award